MYD88 and fatty liver disease: Choi et al. reported that scopoletin (0.01%) ameliorates hyperglycemia and hepatic steatosis in HFD- and STZ-induced diabetic mice through suppression of lipid biosynthesis and the TLR4–MyD88 pathways (Choi et al., 2017).